APA (7th ed.) Citation

M, B., EG, D., Jr, G. L., LJ, S., TM, K., DR, M., . . . JA, J. (2024). Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States. Neurology and therapy, 13(6), 1641. https://doi.org/10.1007/s40120-024-00649-y

Chicago Style (17th ed.) Citation

M, Boustani, Doty EG, Garrison LP Jr, Smolen LJ, Klein TM, Murphy DR, Spargo AW, Belger M, and Johnston JA. "Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States." Neurology and Therapy 13, no. 6 (2024): 1641. https://doi.org/10.1007/s40120-024-00649-y.

MLA (9th ed.) Citation

M, Boustani, et al. "Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States." Neurology and Therapy, vol. 13, no. 6, 2024, p. 1641, https://doi.org/10.1007/s40120-024-00649-y.